Pharmacogenomic Testing: Can Your DNA Tell You Which Psychiatric Medications Will Work?

Psychiatric medication selection has historically involved a significant amount of trial and error. A psychiatrist chooses an antidepressant based on the patient's symptom profile, side effect tolerance, and clinical experience — then waits 4–6 weeks to see if it works. If it doesn't, they try another. For patients with treatment-resistant conditions, this process can stretch over years.

Pharmacogenomic testing — analyzing your DNA to predict how your body will respond to specific medications — promises to make this process more precise. Here's an honest look at what it can and cannot do.

What Pharmacogenomic Testing Measures

Pharmacogenomic (PGx) panels analyze genetic variants in two main categories relevant to psychiatric medications:

Pharmacokinetics: How Your Body Processes Medications

Most psychiatric medications are metabolized primarily by liver enzymes in the cytochrome P450 (CYP) family — particularly CYP2D6, CYP2C19, and CYP3A4. Genetic variants in these enzymes determine whether you are a:

• Poor metabolizer (PM): Enzyme is less active; medications accumulate to higher blood levels, increasing side effect risk
• Intermediate metabolizer (IM): Somewhat reduced enzyme activity
• Normal metabolizer (NM): Standard enzyme activity; typical drug processing
• Rapid/Ultrarapid metabolizer (RM/UM): Enzyme is more active; medications are cleared faster, potentially reducing efficacy at standard doses

This has direct clinical implications. A CYP2D6 poor metabolizer taking a standard dose of an antidepressant may experience side effects that seem inexplicable — until you see that their blood levels are running 3-4x higher than expected. Conversely, a CYP2D6 ultrarapid metabolizer may require higher-than-standard doses to achieve therapeutic blood levels.

Pharmacodynamics: How Medications Affect Your Brain

Genetic variants in neurotransmitter receptors and transporters affect how the brain responds to psychiatric medications at the target level. Key variants include:

• SLC6A4 (serotonin transporter): Some studies suggest variants affect SSRI response, though the evidence is mixed
• COMT: Affects dopamine metabolism in the prefrontal cortex, relevant to ADHD medication response
• MTHFR: Affects folate metabolism; variants may impair the production of neurotransmitter precursors

What the Evidence Shows

The evidence for pharmacogenomic testing in psychiatry is genuinely promising — but also genuinely limited. Here is an honest assessment:

Strong evidence: CYP enzyme testing for metabolizer status is clearly clinically useful. If a patient is a CYP2D6 poor metabolizer, knowing this upfront can prevent weeks of side effects from medications that accumulate excessively. This is established, validated pharmacology.

Moderate evidence: Large randomized controlled trials (notably the GUIDED trial) have found that using pharmacogenomic guidance in medication selection modestly but significantly improves psychiatric outcomes compared to standard care — with a roughly 50% greater chance of achieving response at 8 weeks.

Weaker evidence: The interpretation of pharmacodynamic variants (receptor genetics) is less robust. The associations between individual gene variants and medication response are often small, inconsistent across studies, and may not translate into reliable clinical prediction.

What PGx cannot tell you: Which medication will definitely work for you. Which medication will produce the best clinical outcomes for your specific brain chemistry. Medication response is influenced by many factors beyond genetics — psychosocial context, diagnosis accuracy, placebo response, and unknown biological factors.

How We Use Pharmacogenomic Testing

At Segal Telepsychiatry Network, we offer pharmacogenomic testing as a tool to inform — not replace — clinical judgment. We use it particularly for:

• Patients with a history of multiple medication trials and unclear reasons for failure
• Patients with unusually severe side effects at standard doses
• Patients before starting a new medication, to identify obvious metabolic concerns upfront

The test involves a simple cheek swab and can be processed within 1–2 weeks. Many insurance plans cover PGx testing; our team can verify coverage.

If you're interested in discussing whether pharmacogenomic testing makes sense for your situation, schedule a consultation with one of our providers.

Precision psychiatry is not yet fully realized — but we're closer than we've ever been.